These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 37338126)

  • 1. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy.
    John AO; Ramnath N
    Oncologist; 2023 Sep; 28(9):752-764. PubMed ID: 37338126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.
    Isaacs J; Stinchcombe TE
    Drugs; 2022 Jun; 82(8):855-863. PubMed ID: 35596880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis.
    Wu Y; Hu L; Zhang S; Zhang H
    Technol Cancer Res Treat; 2024; 23():15330338241258164. PubMed ID: 38872482
    [No Abstract]   [Full Text] [Related]  

  • 4. Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study.
    Ratto GB; Costa R; Maineri P; Alloisio A; Piras MT; D'Agostino A; Tripodi G; Rivabella L; Dozin B; Bruzzi P; Melioli G
    Int J Immunopathol Pharmacol; 2011; 24(4):1005-16. PubMed ID: 22230406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
    Christopoulos P
    Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
    Dunne EG; Fick CN; Isbell JM; Chaft JE; Altorki N; Park BJ; Spicer J; Forde PM; Gomez D; Iyengar P; Harpole DH; Stinchcombe TE; Liberman M; Bott MJ; Adusumilli PS; Huang J; Rocco G; Jones DR
    Ann Thorac Surg; 2024 Jul; 118(1):119-129. PubMed ID: 38316378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
    Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
    Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
    Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
    Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
    West HJ; Kim JY
    JAMA Oncol; 2024 Feb; 10(2):249-255. PubMed ID: 38153722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease.
    Sathiyapalan A; Baloush Z; Ellis PM
    Curr Oncol; 2023 Oct; 30(11):9514-9529. PubMed ID: 37999109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
    Lee JM; Tsuboi M; Brunelli A
    Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC.
    Brazel D; Nagasaka M
    Med; 2024 Aug; 5(8):852-855. PubMed ID: 39127033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
    Bunn PA
    Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
    Liu X; Xing H; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer.
    Conroy MR; Dennehy C; Forde PM
    Lung Cancer; 2023 Sep; 183():107314. PubMed ID: 37541935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
    Kang J; Zhang C; Zhong WZ
    Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Top advances of the year: Perioperative therapy for lung cancer.
    Aredo JV; Wakelee HA
    Cancer; 2024 Sep; 130(17):2897-2903. PubMed ID: 38717993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?
    Collazo-Lorduy A; Blanco M; Calvo V; Provencio M
    Curr Opin Pulm Med; 2024 Jul; 30(4):346-351. PubMed ID: 38712693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review.
    Cui S; Wang N; Liang Y; Meng Y; Shu X; Kong F
    Int Immunopharmacol; 2024 Nov; 141():112903. PubMed ID: 39146783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.